Study identifies a new potential target for treating vascular disease

Vascular diseases, including myocardial infarction, stroke, renal failure, and peripheral vascular disease, continue to account for one third of all mortality in the United States, Europe, and the developing world (World Health Organization, 2021). Vascular smooth muscle cell (VSMC) activation plays a crucial role in the development of multiple vascular diseases. In a novel study opens in new tab/window in The American Journal of Pathology opens in new tab/window, published by Elsevier, researchers found that when fragile-X related protein-1 (FXR1) is absent, VSMC proliferate more slowly, become senescent, and scar tissue (neointima) development is reduced. Therefore, drugs targeting FXR1 may treat vascular proliferative diseases.

“Our lab previously reported that expression of FXR1, a muscle-enhanced RNA binding protein that appears to decrease inflammatory transcripts, is increased in injured arteries and in plaque VSMC in human aortas,” explained lead investigator Michael V. Autieri, PhD, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. “However, the role of FXR1 expression in the vascular response to injury had not yet been studied in a relevant animal model of vascular disease, and so we designed our study to explore this further.”

To extend their understanding of the impact of the absence of FXR1, investigators performed RNA-sequencing on FXR1-depleted human VSMCs. Their results suggest that FXR1 appears to stabilize a group of transcripts involved in control of the cell cycle, most of which are associated with proliferation and cell division. In addition, they noted an increase in beta galactosidase and gamma H2AX, molecules indicative of cell senescence.

Next, to understand how the absence of FXR1 would affect vascular occlusive disease, they developed a mouse model to specifically deplete FXR1 in the smooth muscles upon drug induction. The mice were subjected to carotid ligation, which is a model of vascular stenosis. Drug-induced depletion of FXR1 in smooth muscle cells protected the mice against neointima formation following injury. Injured arteries had a gene expression profile similar to human VSMC following FXR1 knockdown.

Caption: A new study shows that when fragile-X related protein-1 (FXR1) is absent, vascular smooth muscle cells (VSMC) proliferate more slowly, become senescent, and scar tissue (neointima) development is reduced. Therefore, drugs targeting FXR1 may treat vascular proliferative diseases (Caption: The American Journal of Pathology).

“These results are the first to suggest that in addition to destabilization of inflammatory transcripts, FXR1 may stabilize cell cycle related genes in VSMC, and absence of FXR1 leads to induction of a senescent phenotype. This supports the hypothesis that FXR1 may mediate vascular disease by regulating stability of proliferative mRNA in VSMC,” commented Dr. Autieri.

The fact that FXR1 stabilized this group of transcripts, while it normally is regarded as an RNA-binding protein that destabilizes transcripts, was surprising to investigators. Additionally, while they expected to see a difference in the knockout mouse phenotype compared to controls, they did not expect such a dramatic result.

“Because we have seen that in the absence of FXR1, VSMC have significantly reduced proliferation and become senescent, drugs that target FXR1 may have implications for modalities to combat vascular proliferative diseases such as atherosclerosis, restenosis, hypertension, and abdominal aortic aneurysm. Given the global increase in cardiovascular diseases in an aging and increasingly sedentary population, it is critical to do everything we can to investigate potential genes and targets that may be exploited to influence disease pathology,” Dr. Autieri concluded.

---

Notes for editors

The article is “Genetic Deletion of FXR1 Reduces Intimal Hyperplasia and Induces Senescence in Vascular Smooth Muscle Cells,” by Cali B. Corbett, Amanda St. Paul, Tani Leigh, Sheri E. Kelemen, Amanda M. Peluzzo, Rachael N. Okune, Satoru Eguchi, Dale S. Haines, and Michael V. Autieri (https://doi.org/10.1016/j.ajpath.2023.01.006 opens in new tab/window). It appears in The American Journal of Pathology, volume 193, issue 5 (May 2023), published by Elsevier.

The article is openly available at https://ajp.amjpathol.org/article/S0002-9440(23)00038-X/fulltext opens in new tab/window.

The study was supported by NIH National Heart, Lung, and Blood Institute grants HL141108 and HL117724.

Full text of the article is also available to credentialed journalists upon request. Contact Eileen Leahy at +1 732 238 3628 or [email protected] opens in new tab/window to request a PDF of the article. To request an interview with the author please contact Michael V. Autieri, PhD, at [email protected] opens in new tab/window, or Jennifer Reardon, Senior Press Officer, Temple Health, at [email protected] opens in new tab/window.

About The American Journal of Pathology

The American Journal of Pathology opens in new tab/window, official journal of the American Society for Investigative Pathology opens in new tab/window, published by Elsevier, seeks high-quality original research reports, reviews, and commentaries related to the molecular and cellular basis of disease. The editors will consider basic, translational, and clinical investigations that directly address mechanisms of pathogenesis or provide a foundation for future mechanistic inquiries. Examples of such foundational investigations include data mining, identification of biomarkers, molecular pathology, and discovery research. High priority is given to studies of human disease and relevant experimental models using molecular, cellular, and organismal approaches. https://ajp.amjpathol.org opens in new tab/window

About Elsevier

As a global leader in scientific information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.

We have supported the work of our research and healthcare communities for more than 140 years. Our 9,500 employees around the world, including 2,500 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 2,900 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy.

Together with the Elsevier Foundation opens in new tab/window, we work in partnership with the communities we serve to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX opens in new tab/window, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.